Generic drugs and brand specialities in epilepsy treatment, are they clinically equivalent? Are there any precautions to take for substitution?;Les médicaments génériques et les médicaments princeps sont-ils équivalents du point de vue clinique? Y a-t-il des précautions d'emploi?

Epilepsies

Volumn 19, Issue 1, 2007, Pages 6-10

  Biraben, Arnaud ^a   Semah, Franck ^b   De Toffol, Bertrand ^c  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^b CENTRE HOSPITALIER SAINTE ANNE   (France)

^c CHU BRETONNEAU   (France)

Author keywords

Anti epileptic drug; Brand; Epilepsy; Generic drugs; Substitution

Indexed keywords

GENERIC DRUG; LAMOTRIGINE; VALPROIC ACID;

CHRONIC DISEASE; ECONOMIC ASPECT; EPILEPSY; HEALTH CARE COST; HUMAN; MEDICAL ERROR; MEDICAL SPECIALIST; PHARMACIST; PHYSICIAN; PRESCRIPTION; REVIEW; SOCIAL ASPECT;

EID: 34247466498     PISSN: 11496576     EISSN: None     Source Type: Journal    
DOI: 10.1684/epi.2007.0073     Document Type: Review

References (29)

1. Assessment : generic substitution for antiepileptic medication. Report of the Therapeutics and Technology Assessment Subcomittee of the American Academy of Neurology. Neurology 1990 ; 40 : 1641-3.
2. Biraben A, de Toffol B, Semah F, Rouault T. Utilisation des médicaments génériques des antiépileptiques en France : résultats d'une enquête aupres des neurologues et revue de la littérature. Rev Neurol (Paris) 2007 ; (sous presse).
3. Burkhardt RT, Leppik IE, Blesi K, Scott S, Gapany SR, Cloyd J-C. Lower phenytoin serum levels in persons switched from brand to generic phenytoin. Neurology 2004 ; 63 : 1494-6.
4. Crawford P, Hall WW, Chappell B, Collings J, Stewart A. Generic prescribing for epilepsy : is it safe? Seizure 1996 ; 5 : 1-5.
5. Dhanaraj M, Jayavelu A. Non-equivalence of bioavailability between generic and branded form of sodium valproate. Neurol India 2004 ; 52 : 398.
6. Gilman JT, Alvarez LA, Duchowny M. Carbamazepine toxicity resulting from generic substitution. Neurology 1993 ; 43 : 2696-7.
7. Goodwin M. The importance of brand continuity in epilepsy drugs. Nurs Times 2005 ; 101 : 26.
8. Haskins LS, Tomaszewski KJ, Crawford P. Patient and physician reactions to generic antiepileptic substitution in the treatment of epilepsy. Epilepsy Behav 2005 ; 7 : 98-105.
9. Jobst BC, Holmes GL. Prescribing antiepileptic drugs. Should patients be switched on the basis of cost? CNS Drugs 2004 ; 18 : 617-28.
10. Koch G, Allen J-P. Untoward effects of generic carbamazepine therapy. Arch Neurol 1978 ; 44 : 578-9.
11. Krämer G, Dennig D, Schmidt D, et al. Generics in antiepileptic drug therapy : What has to be considered? Akt Neurol 2005 ; 32 : 275-8.
12. Lam YW, Ereshefsky L, Toney GB, Gonzales C. Branded versus generic clozapine : bioavailability comparison and interchangeability issues. J Clin Psychiatry 2001 ; 62 : 18-22.
13. Macdonald JT. Breakthrough seizure following substitution of Depakene capsules (Abbott) with a generic product. Neurology 1987 ; 37 : 1885.
14. Mofsen R, Balter J. Case report of the reemergence of psychotic symptoms after conversion from brand-name clozapine to a generic formulation. Clin Ther 2001 ; 23 : 1720-31.
15. National Institute for Clinical Excellence Guideline. The epilepsies : diagnosis and management of the epilepsies in adults in primary and secondary care. Clinical Guideline 2004 ; 20.
16. Oles KS, Penry JK, Smith LD, Anderson RL, Dean JC, Riela AR. Therapeutic bioequivalency study brand name versus generic carbamazepine. Neurology 1992 ; 42 : 1147-53.
17. Olling M, Mesinga TT, Barends DM, Groen C, Lake OA, Meulenbelt J. Bioavailability of carbamazepine from four different products and the occurrence of side effects. Drug Dispos 1999 ; 20 : 19-28.
18. Perruca E, Albani F, Capovilla G, Bernardina BD, Michelucci R. Zaccara. Recommandations of the Italian league against epilepsy working group on generic products of antiepileptic drugs. Epilepsia 2006 ; 47 : 16-20.
19. Revankar SN, Desai ND, Bhatt AD, et al. Comparison of absorption rate and bioavailability of two brands of carbamazepine. J Assoc Physicians India 1999 ; 47 : 699-702.
20. Rosenbaum DH, Rowan AJ, Tuchman L, French JA. Comparative bioavailability of a generic phenytoin and Dilantin. Epilepsia 1994 ; 35 : 656-60.
21. Sachdeo RC, Belendiuk G. Generic versus branded carbamazepine. Lancet 1987 ; 20 : 1432 ; (1).
22. Sherwood-Brown E, Shellhorn E, Suppes T. Gastrointestinal side effects after switch to generic valproic acid. Pharmacopsychiatry 1998 ; 31 : 114.
23. Silpakit O, Amornpichetkoon M, Kaojarern S. Comparative study of bioavailability and clinical efficacy of carbamazepine in epileptic patients. Ann Pharmacother 1997 ; 31 : 548-52.
24. Vadney VJ, Kraushaar KW. Effects of switching from Depakene to generic valproic acid on individuals with mental retardation. Ment Retard 1997 ; 35 : 468-72.
25. Welty TE, Pickering PR, Hale BC, Arazi R. Loss of seizure control associated with generic substitution of carbamazepine. Ann Pharmacoter 1992 ; 26 : 775-7.
26. Wilder BJ, Leppick I, Hietpas TJ, Cloyd JC, Randinitis EJ, Cook J. Effects of food on absorption of Dilantin Kapseal and Mylan extended phenytoin sodium capsules. Neurology 2001 ; 58 : 582-9.
27. Wilner AN. Therapeutic equivalency of generic antiepileptic drugs : results of a survey. Epilepsy Behav 2004 ; 5 : 995-8.
28. Wolf P, May T, et al. Steady state concentrations and diurnal fluctuations of carbamazepine in patients after different slow release formulations. Arzneimittelforschung 1992 ; 42 : 284-8.
29. Yu BP, Chong YS, Maguire GA. Is generic fluoxetine effective? J Affect Disord 2004 ; 81 : 185-6.